Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease

被引：55

作者：

Bartels, A. L. ^{[1
]}

van Berckel, B. N. M. ^{[2
]}

Lubberink, M. ^{[2
]}

Luurtsema, G. ^{[2
]}

Lammertsma, A. A. ^{[2
]}

Leenders, K. L. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands

[2] Vrije Univ Amsterdam, Med Ctr, Dept Nucl Med & PET Res, Amsterdam, Netherlands

来源：

PARKINSONISM & RELATED DISORDERS | 2008年 / 14卷 / 06期

关键词：

Parkinson's disease; blood-brain barrier; P-glycoprotein; verapamil PET;

D O I：

10.1016/j.parkreldis.2007.11.007

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The cause of Parkinson's disease (PD) is unknown. Genetic susceptibility and exposure to environmental toxins contribute to specific neuronal loss in PD. Decreased blood-brain barrier (BBB) P-glycoprotein (P-gp) efflux function has been proposed as a possible causative link between toxin exposure and PD neurodegeneration. In the present study BBB P-gp function was investigated in viva in 10 early stage PD patients and 8 healthy control subjects using (R)-[C-11]-verapamil and PET. Cerebral volume of distribution (V-d) of verapamil was used as measure of P-gp function. Both region of interest (ROI) analysis and voxel analysis using statistical parametric mapping (SPM) were performed to assess regional brain P-gp function. In addition, MDR1 genetic polymorphism was assessed. In the present study, a larger variation in V-d of (R)-[C-11]-verapamil was seen in the PD group as compared to the control group. However, decreased BBB P-gp function in early stage PD patients could not be confirmed. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：505 / 508

页数：4

共 12 条

[1]

Braak H, 2000, J NEUROL, V247, P3

[2]

Isolation of endothelial cells from brain, lung, and kidney:: Expression of the multidrug resistance P-glycoprotein isoforms [J].

Demeule, M ;

Labelle, M ;

Régina, A ;

Berthelet, F ;

Béliveau, R .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (03) :827-834

[3]

Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease [J].

Drozdzik, M ;

Bialecka, M ;

Mysliwiec, K ;

Honczarenko, K ;

Stankiewicz, J ;

Sych, Z .

PHARMACOGENETICS, 2003, 13 (05) :259-263

[4]

Rapid modulation of p-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-α and lipopolysaccharide [J].

Hartz, AMS ;

Bauer, B ;

Fricker, G ;

Miller, DS .

MOLECULAR PHARMACOLOGY, 2006, 69 (02) :462-470

[5]

Hendrikse NH, 1999, J NUCL MED, V40, p261P

[6]

Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo [J].

Kortekaas, R ;

Leenders, KL ;

van Oostrom, JCH ;

Vaalburg, W ;

Bart, J ;

Willemsen, ATM ;

Hendrikse, NH .

ANNALS OF NEUROLOGY, 2005, 57 (02) :176-179

[7]

Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET [J].

Lubberink, Mark ;

Luurtsema, Gert ;

van Berckel, Bart N. M. ;

Boellaard, Ronald ;

Toornvliet, Rolf ;

Windhorst, Albert D. ;

Franssen, Eric J. F. ;

Lammertsma, Adriaan A. .

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2007, 27 (02) :424-433

[8]

(R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function:: in vitro and in vivo evaluation [J].

Luurtsema, G ;

Molthoff, CFM ;

Windhorst, AD ;

Smit, JW ;

Keizer, H ;

Boellaard, R ;

Lammertsma, AA ;

Franssen, EJF .

NUCLEAR MEDICINE AND BIOLOGY, 2003, 30 (07) :747-751

[9]

Transport of [3H]MPP+ in an immortalized rat brain microvessel endothelial cell line (RBE 4) [J].

Martel, F ;

Calhau, C ;

Soares-da-Silva, P ;

Azevedo, I .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 363 (01) :1-10

[10]

Etiology of Parkinson's disease [J].

Schapira, Anthony H. V. .

NEUROLOGY, 2006, 66 (10) :S10-S23

← 1 2 →